T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-...
שמור ב:
| Principais autores: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI AG
2022-09-01
|
| סדרה: | Vaccines |
| נושאים: | |
| גישה מקוונת: | https://www.mdpi.com/2076-393X/10/9/1494 |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
